Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 3/20 | 0.81 |
| ▸ | MEN1 | O00255 | 3/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.81 |
| ▸ | MAPT | P10636 | 3/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.81 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.81 |
| ▸ | THPO | P40225 | 1/20 | 0.81 |
| ▸ | CACNA1F | O60840 | 7/20 | 0.76 |
| ▸ | CACNA1D | Q01668 | 7/20 | 0.76 |
| ▸ | CACNA1S | Q13698 | 7/20 | 0.76 |
| ▸ | CACNA1C | Q13936 | 7/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7275184 | 0.96 | CACNA1F (0.82) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL7280911 | 0.94 | MEN1 (0.75) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL3436017 | 0.94 | HIF1A (0.78) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL7430479 | 0.94 | MEN1 (0.80) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL3435816 | 0.93 | CACNA1F (0.88) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL11179186 | 0.93 | HIF1A (0.69) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL10576375 | 0.92 | CACNA1F (0.79) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL7290444 | 0.92 | CACNA1F (0.79) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL7275200 | 0.92 | CACNA1F (0.76) | HIF1AMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL7275191 | 0.92 | CACNA1F (0.76) | HIF1AMEN1KMT2AMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115572253-A | Synthesis process of manidipine hydrochloride raw material medicine | 许昌恒生制药有限公司 | 2023-01-06 | — | — | CN | claimed |
| CN-115572253-A | Synthesis process of manidipine hydrochloride raw material medicine | 许昌恒生制药有限公司 | 2023-01-06 | — | — | CN | disclosed |
| US-8163907-B2 | Dihydropyridine calcium antagonist compounds, preparation methods, and medical uses thereof | COSUNTER PHARMACEUTICAL COMPANY (CN) | 2012-04-24 | — | — | US | disclosed |
| US-8163907-B2 | Dihydropyridine calcium antagonist compounds, preparation methods, and medical uses thereof | COSUNTER PHARMACEUTICAL COMPANY (CN) | 2012-04-24 | — | — | US | disclosed |
| CN-101525314-B | Dihydropyridine calcium antagonist compound, preparation method and medicinal application thereof | FUJIAN COSUNTER PHARMACEUTICAL CO LTD | 2012-01-04 | — | — | CN | disclosed |
| US-20110201811-A1 | DIHYDROPYRIDINE CALCIUM ANTAGONIST COMPOUNDS, PREPARATION METHODS, AND MEDICAL USES THEREOF | COSUNTER PHARMACEUTICAL COMPANY (CN) | 2011-08-18 | — | — | US | disclosed |
| US-20110201811-A1 | DIHYDROPYRIDINE CALCIUM ANTAGONIST COMPOUNDS, PREPARATION METHODS, AND MEDICAL USES THEREOF | COSUNTER PHARMACEUTICAL COMPANY (CN) | 2011-08-18 | — | — | US | disclosed |
| CN-101525314-A | Dihydropyridine calcium antagonist compound, preparation method and medicinal application thereof | FUJIAN COSUNTER PHARMACEUTICAL | 2009-09-09 | — | — | CN | disclosed |
| US-7585978-B2 | Processes of manufacturing substituted-1,4-dihydropyridines, improved aqueous solutions thereof, and processes of manufacturing the solutions | NAVINTA LLC (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080125595-A1 | Single step one pot process for making nicardipine hydrochloride from 3-nitro-benzaldehyde, methyl aminocrotonate, and N-benzyl-N-methylaminoethyl acetoacetate; aqueous, injectable isotonic solution of nicardipine hydrochloride, L-arginine, and a sugar alcohol | NAVINTA LLC. | 2008-05-29 | — | — | US | disclosed |
| US-4705797-A | HYPOTENSIVE AGENTS, VASODILATORS | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1987-11-10 | — | — | US | disclosed |
| US-4705794-A | Ischaemia or hypoxia controlling compositions containing pyridinecarboxylic acid esters | BAYER AKTIENGESELLSCHAFT (DE) | 1987-11-10 | — | — | US | disclosed |
| US-4634712-A | Antihypertensive esters of 1,4-dihydro-2,6-dimethyl-3-(alkoxycarbonyl or alkoxyalkoxycarbonyl)-4-(substituted phenyl)-pyridine-5-carboxylic acid | RECORDATI S.A. (CH) | 1987-01-06 | — | — | US | disclosed |
| EP-0184841-A2 | 1,4-Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions containing same | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1986-06-18 | — | — | EP | disclosed |
| US-4565824-A | Certain nitratoalkyl ester dihydropyridines having antihypertensive properties | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-21 | — | — | US | disclosed |
| US-4564619-A | ANTICOAGULANTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-01-14 | — | — | US | disclosed |
| EP-0164213-A1 | Esters of 1,4-dihydro-2,6-dimethyl-3-(alkoxycarbonyl or alkoxyalkoxycarbonyl)-4-(substituted phenyl)-pyridine-5-carboxylic acid | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1985-12-11 | — | — | EP | disclosed |
| EP-0153016-A2 | Asymmetrical diesters of 1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1985-08-28 | — | — | EP | disclosed |
| US-4497821-A | Medicaments having antihypoxic and ischaemia-protective activity | BAYER AKTIENGESELLSCHAFT (DE) | 1985-02-05 | — | — | US | disclosed |
| US-3985758-A | 1,4-Dihydropyridine derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201811-A1 | DIHYDROPYRIDINE CALCIUM ANTAGONIST COMPOUNDS, PREPARATION METHODS, AND MEDICAL USES THEREOF | RYR1, CACNA1E, CACNA1C | HIF1A 2995/4885MEN1 434/4885KMT2A 3869/4885 |
| US-20080125595-A1 | Single step one pot process for making nicardipine hydrochloride from 3-nitro-benzaldehyde, methyl aminocrotonate, and N-benzyl-N-methylaminoethyl acetoacetate; aqueous, injectable isotonic solution of nicardipine hydrochloride, L-arginine, and a sugar alcohol | ADH1C, PRMT1, SCN1B | HIF1A 3962/4885MEN1 788/4885KMT2A 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.